BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23069814)

  • 1. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
    Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
    JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
    Talpur R; Venkatarajan S; Duvic M
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):591-7. PubMed ID: 25068889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
    Kim EJ; Guitart J; Querfeld C; Girardi M; Musiek A; Akilov OE; Angello JT; Bailey WL; Geskin LJ
    Am J Clin Dermatol; 2021 May; 22(3):407-414. PubMed ID: 33656660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study.
    Geskin LJ; Kim EJ; Angello JT; Kim YH
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):119-124.e4. PubMed ID: 33358692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides.
    Querfeld C; Scarisbrick JJ; Assaf C; Guenova E; Bagot M; Ortiz-Romero PL; Quaglino P; Bonizzoni E; Hodak E
    Dermatology; 2022; 238(2):347-357. PubMed ID: 34091453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
    de Quatrebarbes J; Estève E; Bagot M; Bernard P; Beylot-Barry M; Delaunay M; D'Incan M; Souteyrand P; Vaillant L; Cordel N; Courville P; Joly P
    Arch Dermatol; 2005 Sep; 141(9):1117-20. PubMed ID: 16172308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
    Liner K; Brown C; McGirt LY
    Drug Des Devel Ther; 2018; 12():241-254. PubMed ID: 29440874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.
    Kim EJ; Geskin L; Guitart J; Querfeld C; Girardi M; Musiek A; Mink DR; Williams MJ; Angello JT; Bailey WL
    J Am Acad Dermatol; 2020 Sep; 83(3):928-930. PubMed ID: 32089294
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
    Kim YH; Martinez G; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel.
    Benjamin Chase A; Markel K; Tawa MC
    Clin J Oncol Nurs; 2015 Dec; 19(6):E131-9. PubMed ID: 26583648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
    Querfeld C; Geskin LJ; Kim EJ; Scarisbrick JJ; Quaglino P; Papadavid E; Angello JT; Ortiz-Romero PL
    J Invest Dermatol; 2021 Jun; 141(6):1601-1604.e2. PubMed ID: 33347924
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
    Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
    JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
    Kim EJ; Mangold AR; DeSimone JA; Wong HK; Seminario-Vidal L; Guitart J; Appel J; Geskin L; Lain E; Korman NJ; Zeitouni N; Nikbakht N; Dawes K; Akilov O; Carter J; Shinohara M; Kuzel TM; Piette W; Bhatia N; Musiek A; Pariser D; Kim YH; Elston D; Boh E; Duvic M; Huen A; Pacheco T; Zwerner JP; Lee ST; Girardi M; Querfeld C; Bohjanen K; Olsen E; Wood GS; Rumage A; Donini O; Haulenbeek A; Schaber CJ; Straube R; Pullion C; Rook AH; Poligone B
    JAMA Dermatol; 2022 Sep; 158(9):1031-1039. PubMed ID: 35857290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Mycosis Fungoides with Topical Chlormethine/Mechlorethamine Gel: A Columbia University Cutaneous Lymphoma Center Experience.
    Garcia-Saleem TJ; Stonesifer CJ; Khaleel AE; Geskin LJ
    Acta Derm Venereol; 2021 Sep; 101(9):adv00544. PubMed ID: 34436621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.
    Querfeld C; Scarisbrick JJ; Assaf C; Kim YH; Guitart J; Quaglino P; Hodak E
    Am J Clin Dermatol; 2022 Jul; 23(4):561-570. PubMed ID: 35536441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
    Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
    Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
    Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
    Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In brief: mechlorethamine gel (Valchlor) for cutaneous T-Cell lymphoma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66. PubMed ID: 25988964
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides.
    Delfau-Larue MH; Dalac S; Lepage E; Petrella T; Wechsler J; Farcet JP; Bagot M
    Blood; 1998 Nov; 92(9):3376-80. PubMed ID: 9787176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrogen mustard gel-induced inflammation triggers lymphomatoid papulosis in patients with mycosis fungoides.
    Trager MH; Chen C; Husain S; Geskin LJ
    J Dermatol; 2020 May; 47(5):546-550. PubMed ID: 32100361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.